L
Laurent Garderet
Researcher at University of Paris
Publications - 270
Citations - 15534
Laurent Garderet is an academic researcher from University of Paris. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 54, co-authored 252 publications receiving 13060 citations. Previous affiliations of Laurent Garderet include National and Kapodistrian University of Athens & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Valérie Lauwers-Cances,Gerald Marit,Denis Caillot,Philippe Moreau,Thierry Facon,Anne-Marie Stoppa,Cyrille Hulin,Lofti Benboubker,Laurent Garderet,Olivier Decaux,Serge Leyvraz,Marie-Christiane Vekemans,Laurent Voillat,Mauricette Michallet,Brigitte Pegourie,Charles Dumontet,Murielle Roussel,Xavier Leleu,Claire Mathiot,Catherine Payen,Hervé Avet-Loiseau,Jean-Luc Harousseau +22 more
TL;DR: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma.
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau,Tamás Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Deborah Berg,J. Lin,Alessandra Di Bacco,Ai Min Hui,Helgi van de Velde,Paul G. Richardson +25 more
TL;DR: The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús F. San Miguel,Jesús F. San Miguel,Katja Weisel,Philippe Moreau,Martha Q. Lacy,Kijoung Song,Michel Delforge,Lionel Karlin,Hartmut Goldschmidt,Anne Banos,Albert Oriol,Adrian Alegre,Christopher T. Chen,Michele Cavo,Laurent Garderet,Valentina Ivanova,Joaquin Martinez-Lopez,Andrew R. Belch,Antonio Palumbo,Steve Schey,Pieter Sonneveld,Xiaoyan Yu,Lars Sternas,Christian Jacques,Mohamed H. Zaki,Meletios A. Dimopoulos +25 more
TL;DR: Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients withRefractory or relapsed and refractory multiple myeloma.